Research programme: hepatitis B therapeutics - Assembly Biosciences/Indiana University

Drug Profile

Research programme: hepatitis B therapeutics - Assembly Biosciences/Indiana University

Alternative Names: ABI-H2158; Antiviral therapeutics - Assembly Biosciences; Core Protein Allosteric Modulators; CpAMs

Latest Information Update: 20 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Indiana University
  • Developer Assembly Biosciences; Indiana University
  • Class Antivirals; Small molecules
  • Mechanism of Action Viral core protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 20 Aug 2018 Preclinical development in Hepatitis-B is underway in USA (PO) (9247174; Assembly Biosciences Pipeline)
  • 07 May 2018 Assembly Biosciences plans a phase Ia trial of ABI H2158 for Hepatitis B (In volunteers) in USA (PO) in the fourth quarter of 2018
  • 25 Sep 2017 Assembly Biosciences plans a phase Ia trial for Hepatitis B infection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top